Literature DB >> 23996530

Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype.

Wook-Jin Yang1, Min-Ji Song, Eun Young Park, Jong-Joo Lee, Joo-Hong Park, Keunhee Park, Jong Hoon Park, Hyoung-Pyo Kim.   

Abstract

ABCG2 is a member of the ATP binding cassette (ABC) transmembrane proteins that plays an important role in stem cell biology and drug resistance of cancer cells. In this study, we investigated how expression of human ABCG2 gene is regulated in lung cancer A549 cells. Binding of Sp1 and Sp3 transcription factors to the ABCG2 promoter in vitro and in vivo was elucidated by electrophoretic mobility shift assay and chromatin immunoprecipitation assay. The ABCG2 promoter activity was impaired when Sp1 sites were mutated but was enhanced by overexpression of Sp1 or Sp3 proteins. Knockdown of Sp1 or Sp3 expression by short interfering RNA significantly decreased the expression of ABCG2 mRNA and protein, resulting in attenuated formation of the side population in A549 cells. In addition, Sp1 inhibition in vivo by mithramycin A suppressed the percentage of the side population fraction and sphere forming activities of A549 cells. Moreover, inhibiting Sp1- or Sp3-dependent ABCG2 expression caused chemosensitization to the anticancer drug cisplatin. Collectively, our results demonstrate that Sp1 and Sp3 transcription factors are the primary determinants for activating basal transcription of the ABCG2 gene and play an important role in maintaining the side population phenotype of lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996530      PMCID: PMC3887993          DOI: 10.1007/s10059-013-0191-x

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  30 in total

1.  Identification of the promoter region of the human betaIGH3 gene.

Authors:  Ching Yuan; Mei-Chuan Yang; Emily J Zins; Christopher S Boehlke; Andrew J W Huang
Journal:  Mol Vis       Date:  2004-05-18       Impact factor: 2.367

2.  Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.

Authors:  Kumie Kage; Satomi Tsukahara; Tomomi Sugiyama; Sakiyo Asada; Etsuko Ishikawa; Takashi Tsuruo; Yoshikazu Sugimoto
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

3.  Accessible chromatin structure permits factors Sp1 and Sp3 to regulate human TGFBI gene expression.

Authors:  Jong-Joo Lee; Keunhee Park; Myeong Heon Shin; Wook-Jin Yang; Min-Ji Song; Joo-Hong Park; Tai-Soon Yong; Eung Kweon Kim; Hyoung-Pyo Kim
Journal:  Biochem Biophys Res Commun       Date:  2011-04-30       Impact factor: 3.575

4.  ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Authors:  Joel G Turner; Jana L Gump; Chunchun Zhang; James M Cook; Douglas Marchion; Lori Hazlehurst; Pamela Munster; Michael J Schell; William S Dalton; Daniel M Sullivan
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

5.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.

Authors:  Christian W Scharenberg; Michael A Harkey; Beverly Torok-Storb
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

6.  The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.

Authors:  Shin Hamada; Kennichi Satoh; Morihisa Hirota; Atsushi Kanno; Jun Umino; Hiromichi Ito; Atsushi Masamune; Kazuhiro Kikuta; Kiyoshi Kume; Tooru Shimosegawa
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

7.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

8.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

Authors:  Kenneth K W To; Robert W Robey; Turid Knutsen; Zhirong Zhan; Thomas Ried; Susan E Bates
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

9.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

10.  Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.

Authors:  Yun-Ju Chen; Wei-Chien Huang; Ya-Ling Wei; Sheng-Chieh Hsu; Ping Yuan; Heather Y Lin; Ignacio I Wistuba; J Jack Lee; Chia-Jui Yen; Wu-Chou Su; Kwang-Yu Chang; Wen-Chang Chang; Tse-Chuan Chou; Chao-Kai Chou; Chang-Hai Tsai; Mien-Chie Hung
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

View more
  18 in total

Review 1.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

Review 2.  Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies.

Authors:  Yue Zheng; Laduona Wang; Limei Yin; Zhuoran Yao; Ruizhan Tong; Jianxin Xue; You Lu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Interindividual Regulation of the Breast Cancer Resistance Protein/ABCG2 Transporter in Term Human Placentas.

Authors:  Kristin M Bircsak; Jamie E Moscovitz; Xia Wen; Faith Archer; Poi Yu Sofia Yuen; Moiz Mohammed; Naureen Memon; Barry I Weinberger; Laura M Saba; Anna M Vetrano; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2018-01-31       Impact factor: 3.922

4.  Sp1 is over-expressed in nasopharyngeal cancer and is a poor prognostic indicator for patients receiving radiotherapy.

Authors:  Jun Wang; Min Kang; Yu-Tao Qin; Zhu-Xin Wei; Jing-Jian Xiao; Ren-Sheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.

Authors:  Mahadev Rao; Scott M Atay; Vivek Shukla; Young Hong; Trevor Upham; R Taylor Ripley; Julie A Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J Peer; Tristan Sissung; William D Figg; Assunta De Rienzo; Raphael Bueno; David S Schrump
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

6.  Regulation of a disintegrins and metalloproteinase with thrombospondin motifs 7 during inflammation in nucleus pulposus (NP) cells: role of AP-1, Sp1 and NF-κB signaling.

Authors:  Xiaofei Wang; Chunhai Li; Anjing Liang; Yan Peng; Jianchao Sun; Dongsheng Huang; Kang Xu; Wei Ye
Journal:  Inflamm Res       Date:  2016-08-11       Impact factor: 4.575

7.  MiR-24 enhances radiosensitivity in nasopharyngeal carcinoma by targeting SP1.

Authors:  Min Kang; Jingjian Xiao; Jun Wang; Pingting Zhou; Tingting Wei; Tingting Zhao; Rensheng Wang
Journal:  Cancer Med       Date:  2016-02-29       Impact factor: 4.452

8.  Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.

Authors:  Juan Tornin; Lucia Martinez-Cruzado; Laura Santos; Aida Rodriguez; Luz-Elena Núñez; Patricia Oro; Maria Ana Hermosilla; Eva Allonca; Maria Teresa Fernández-García; Aurora Astudillo; Carlos Suarez; Francisco Morís; Rene Rodriguez
Journal:  Oncotarget       Date:  2016-05-24

9.  ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma.

Authors:  Jun Li; Jie Ao; Kai Li; Jie Zhang; Yanyan Li; Le Zhang; Yuyan Wei; Di Gong; Junping Gao; Weiwei Tan; Lugang Huang; Lunxu Liu; Ping Lin; Yuquan Wei
Journal:  Cell Death Dis       Date:  2016-10-20       Impact factor: 8.469

10.  Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells.

Authors:  Tongfa Ju; Huicheng Jin; Rongchao Ying; Qi Xie; Chunhua Zhou; Daquan Gao
Journal:  Mol Med Rep       Date:  2017-07-14       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.